Literature DB >> 29904153

Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.

Zachary J Brown1, Bernd Heinrich1, Tim F Greten2.   

Abstract

Mouse models are the basis of preclinical and translational research in hepatocellular carcinoma (HCC). Multiple methods exist to induce tumour formation in mice, including genetically engineered mouse models, chemotoxic agents, intrahepatic or intrasplenic injection of tumour cells and xenograft approaches. Additionally, as HCC generally develops in the context of diseased liver, methods exist to induce liver disease in mice to mimic viral hepatitis, fatty liver disease, fibrosis, alcohol-induced liver disease and cholestasis. Similar to HCC in humans, response to therapy in mouse models is monitored with imaging modalities such as CT or MRI, as well as additional techniques involving bioluminescence. As immunotherapy is increasingly applied to HCC, mouse models for these approaches are required for preclinical data. In studying cancer immunotherapy, it is important to consider aspects of antitumour immune responses and to produce a model that mimics the complexity of the immune system. This Review provides an overview of the different mouse models of HCC, presenting techniques to prepare an HCC mouse model and discussing different approaches to help researchers choose an appropriate model for a specific hypothesis. Specific aspects of immunotherapy research in HCC and the applied mouse models in this field are also highlighted.

Entities:  

Mesh:

Year:  2018        PMID: 29904153     DOI: 10.1038/s41575-018-0033-6

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  54 in total

Review 1.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

2.  Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen.

Authors:  Rkia El-Kharrag; Randy Owen; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2019-03-14

Review 3.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

4.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Authors:  Li-Chuan Chan; Chia-Wei Li; Weiya Xia; Jung-Mao Hsu; Heng-Huan Lee; Jong-Ho Cha; Hung-Ling Wang; Wen-Hao Yang; Er-Yen Yen; Wei-Chao Chang; Zhengyu Zha; Seung-Oe Lim; Yun-Ju Lai; Chunxiao Liu; Jielin Liu; Qiongzhu Dong; Yi Yang; Linlin Sun; Yongkun Wei; Lei Nie; Jennifer L Hsu; Hui Li; Qinghai Ye; Manal M Hassan; Hesham M Amin; Ahmed O Kaseb; Xin Lin; Shao-Chun Wang; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

Review 5.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

6.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

7.  An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.

Authors:  Agrin Moeini; Sara Torrecilla; Victoria Tovar; Carla Montironi; Carmen Andreu-Oller; Judit Peix; Mónica Higuera; Dominik Pfister; Pierluigi Ramadori; Roser Pinyol; Manel Solé; Mathias Heikenwälder; Scott L Friedman; Daniela Sia; Josep M Llovet
Journal:  Gastroenterology       Date:  2019-07-22       Impact factor: 22.682

8.  HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma.

Authors:  Xiaolei Hao; Yongyan Chen; Lu Bai; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2019-11-25       Impact factor: 11.530

Review 9.  The Liver-Immunity Nexus and Cancer Immunotherapy.

Authors:  James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud
Journal:  Clin Cancer Res       Date:  2021-07-20       Impact factor: 12.531

10.  Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.

Authors:  Bernd Heinrich; Zachary J Brown; Laurence P Diggs; Mathias Vormehr; Chi Ma; Varun Subramanyam; Umberto Rosato; Benjamin Ruf; Juliane S Walz; John C McVey; Simon Wabitsch; Qiong Fu; Su Jong Yu; Qianfei Zhang; Chunwei W Lai; Ugur Sahin; Tim F Greten
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.